Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$32.43 +0.74%

+$0.18 today

Market cap
$1.77B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 1.00M

Average 0.84M

Returns on capital

Maze Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-36.9%

avg -280.6%

ROIC

-37.7%

avg -65.2%

ROA

-33.0%

avg -57.1%

Analysis

ROA is currently the strongest return metric at -33.0% versus its period average of -57.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jason V. Coloma

Chief Executive Officer & DirectorUSD 1.09M5012.96K0.02%

Harold S. Bernstein

President of Research & Development and Chief Medical OfficerUSD 874.58K66——

Courtney J. Phillips

General Counsel & Corporate SecretaryUSD 354.78K51——

Misbah Tahir

CFO & Principal Accounting OfficerUSD 304.94K5120.00K0.04%

Andrew Good

VP & Corporate Controller————

Maarten Hoek

Chief Scientific Officer————

Vipin Vijayakumar

Senior Vice President of Technology and Business Operations————

Winston Tse

Senior Vice President of Drug Discovery————

Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain—63——

Susan Limb

Senior Vice President of Clinical Development————

Matt Krause

Senior Vice President of Human Resources————

Atul Dandekar

Chief Strategy & Business Officer—540<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

92

$19.58M

Net Transaction Value

−$19.58M

Net selling

Most Active

Coloma Jason V

29 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 2, 26

Coloma Jason V

Indirect

Sell$68K
Nov 2, 26

Coloma Jason V

Indirect

Sell$10.4K
Nov 2, 26

Coloma Jason V

Indirect

Sell$166K
Nov 2, 26

Coloma Jason V

Indirect

Sell$799.4K
Oct 29, 26

Dandekar Atul

Direct

Sell$240.5K
Oct 1, 26

Bernstein Harold

Direct

Sell$434.7K
Oct 1, 26

Coloma Jason V

Indirect

Sell$862.2K
Oct 1, 26

Coloma Jason V

Indirect

Sell$70.1K
Sep 29, 26

Dandekar Atul

Direct

Sell$202.9K
Sep 4, 26

Bernstein Harold

Direct

Sell$254.5K

1–10 of 92

Summary

Insiders reported 0 buys worth $0.00 and 92 sells worth $19.58M over the last 12 months. That adds up to net selling of $19.58M. Coloma Jason V was the most active insider with 29 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Maze Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MAZE's management, answered from reported figures.

Who manages MAZE?

Maze Therapeutics, Inc. (MAZE) lists 12 active executives. The top listed executive is Misbah Tahir, CFO & Principal Accounting Officer.

Are MAZE insiders buying or selling?

Recent insider activity shows net buying of $1.57M.